MAXIMUS Inc. (MMS) Drops 6.01% on February 05

Equities Staff |

MAXIMUS Inc. (MMS) was one of the Russell 2000's biggest losers for Friday February 05 as the stock slid 6.01% to $47.38, a loss of $-3.03 per share. Starting at an opening price of $49.80 a share, the stock traded between $46.85 and $50.50 over the course of the trading day. Volume was 1.3 million shares over 8,832 trades, against an average daily volume of 539,460 shares and a total float of 65.33 million.

The losses send MAXIMUS Inc. down to a market cap of $3.1 billion. In the last year, MAXIMUS Inc. has traded between $70.00 and $47.95, and its 50-day SMA is currently $54.83 and 200-day SMA is $61.61.

The stock has a P/E Ratio of 22.4.

Maximus Inc provides business process services to government health and human services agencies in the United States and to foreign governments.

MAXIMUS Inc. is based out of Reston, VA and has some 17,000 employees. Its CEO is Richard A. Montoni.

For a complete fundamental analysis analysis of MAXIMUS Inc., check out’s Stock Valuation Analysis report for MMS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…